YM155 (Sepantronium Bromide)

For research use only.

Catalog No.S1130

127 publications

YM155 (Sepantronium Bromide) Chemical Structure

CAS No. 781661-94-7

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 447 In stock
USD 770 In stock
USD 1270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's YM155 (Sepantronium Bromide) has been cited by 127 publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 M4LC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnqO|IhcA>? M{D2bWROW09? NITDTW1KSzVyPUCuNFA6KMLzIECuNFAxQSEQvF2= NFn6TWYzPTZ3OUezNS=>
M-07e NF3WbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVS3NkBp M{jRb2ROW09? M1\id2lEPTB;MD6wOFAhyrFiMD6wNVMh|ryP NGfaN|MzPTZ3OUezNS=>
THP-1 M3XuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DEZ|czKGh? NVroflg1TE2VTx?= NWH2WlB7UUN3ME2wMlA2OSEEsTCwMlAyOyEQvF2= M1i5UFI2PjV7N{Ox
CMK MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW3NkBp NYnuWHJlTE2VTx?= NHTxOIFKSzVyPUCuNFU{KMLzIECuNFA6KM7:TR?= NFfKXFQzPTZ3OUezNS=>
MV4-11 M2nleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVi3NkBp M2XxRmROW09? MmfZTWM2OD1yLkC1OUDDuSByLkCyPEDPxE1? M2PNR|I2PjV7N{Ox
AML-193 NGDjbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW1O|IhcA>? MkDZSG1UVw>? Moi3TWM2OD1yLkS2NkDDuSByLkC2NEDPxE1? NXvYdFJCOjV4NUm3N|E>
HL-60 NHzPRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjUZZdGPzJiaB?= MVvEUXNQ NHHlZWVKSzVyPUCuNFAyKMLzIECuNFAxOiEQvF2= MV2yOVY2QTd|MR?=
ML-2 NGTpS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X6UVczKGh? NUG0SVJ4TE2VTx?= MWPJR|UxRTBwMEC5JOKyKDBwMECyJO69VQ>? M1ixeFI2PjV7N{Ox
OCI/AML3 M4HSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjB[Fc4OiCq NEXkVXRFVVOR NVzGTGNpUUN3ME2wMlAyOSEEsTCwMlAxOiEQvF2= MoGzNlU3PTl5M{G=
HEL NGmweGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\mUlczKGh? NVP5OFF7TE2VTx?= NFPFdHJKSzVyPUCuOVU6KMLzIECuNFM5KM7:TR?= MXyyOVY2QTd|MR?=
ME-1 MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYS3NkBp NUPRRpJKTE2VTx?= NUXsd5hxUUN3ME2wMlY5PCEEsTCwMlE4QSEQvF2= NFfsOGIzPTZ3OUezNS=>
THP-1 MVzBdI9xfG:|aYOgRZN{[Xl? NVnQSINFOcLizszN NWDoWG9IPzJiaB?= NVP0Z|J{TE2VTx?= Mnn0bY5lfWOnczDhdI9xfG:|aYO= NVXnW2MyOjV4NUm3N|E>
M-07e MnzpSpVv[3Srb36gRZN{[Xl? NE[1WIwx6oDVMdMg{txO Mne0O|IhcA>? MWrEUXNQ MnXIbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= NWLTeo4xOjV4NUm3N|E>
THP-1 NE\Vd5ZHfW6ldHnvckBCe3OjeR?= NGrxN2Yx6oDVMdMg{txO MnXuO|IhcA>? MVHEUXNQ M{nvS4lv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= M{XjNlI2PjV7N{Ox
CMK MofaSpVv[3Srb36gRZN{[Xl? NXrrNYtTOOLCk{JCpO69VQ>? Mn\hO|IhcA>? MX7EUXNQ NV\yfplDcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> NY\KXZVqOjV4NUm3N|E>
AML-193 NG[3NnVHfW6ldHnvckBCe3OjeR?= MmTKNQKBmzIEoN88US=> NFHlS5M4OiCq NIPtVZlFVVOR M37wUYlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NHPmT3EzPTZ3OUezNS=>
Kasumi-1 NWn4PYlTTnWwY4Tpc44hSXO|YYm= NIT4VIYx6oDVMdMg{txO NYrnSZlxPzJiaB?= MYDEUXNQ MWHpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw NFjsbYUzPTZ3OUezNS=>
MV4-11 NELFZW1HfW6ldHnvckBCe3OjeR?= M2OwOFDjiJNzwrFOwG0> NVPFUWROPzJiaB?= NWHwS2lSTE2VTx?= MVHpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw Mm\6NlU3PTl5M{G=
MUG-Chor  NXvBZ4tLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTaNE02KM7:TR?= MU[yOE81QCCq M{DVPGlEPTB;Nz6wOgKBkW6PIH\vdkA1QGh? NEPkfFUzPTZ2MEG4OS=>
U-CH1  MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jTU|AuPSEQvF2= NFv4VnEzPC92ODDo MoHKTWM2OD17LkCz5qCKdk1iZn;yJFQ5cA>? NVLGWGlbOjV4NECxPFU>
KATOIII MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVixNE8zOCCwTR?= Mm\0OFghcA>? M{PvcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFTxUXQzPTZ|NUC1OS=>
AGS  NVLCNYp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPIVpAyOC9{MDDuUS=> NHfESHA1QCCq M3PmbYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWTpfIhGOjV4M{WwOVU>
SACC-83 MVzGeY5kfGmxbjDBd5NigQ>? MYm1JI5O MV20PEBp M3:xfoRm[3KnYYPld{BvfWOuZXHyJIV5eHKnc4Ppc44hd2ZiSFnGMVHPuQ>? Mnj4NlU1QDV4M{W=
INA-6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHEd|AxNTVyMDDuUS=> M2PRRVQ5KGh? MnO4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHHGUpkzPTJ7Nkm3PC=>
U-266 M13abmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD2V3kxNTVyMDDuUS=> Mn;SOFghcA>? MnXobY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NV75SXZqOjV{OU[5O|g>
MOLP-8 Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP4UWRxOC13MECgcm0> MUW0PEBp M3;USYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mm\LNlUzQTZ7N{i=
HG-1 NHvo[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknwNE02ODBibl2= M1WyXVQ5KGh? M2fCRolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYnQUHRzOjV{OU[5O|g>
NCI-H929 NGTMV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1njfFAuPTByIH7N NF7YdIQ1QCCq Mkm2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWKyOVI6Pjl5OB?=
OPM-2 NH;mWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7k[W0xNTVyMDDuUS=> NWHQclNIPDhiaB?= MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{PVO|I2Ojl4OUe4
L-363 NWnzT3M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TXbFAuPTByIH7N M2TlZVQ5KGh? MmD2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWqyOVI6Pjl5OB?=
MOLP-2 M{HTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLRNE02ODBibl2= MXy0PEBp NUPnbGRHcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MX6yOVI6Pjl5OB?=
KMS-12-BM NGjmfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[xZ|AuPTByIH7N MVK0PEBp NVL2c2VbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mnz3NlUzQTZ7N{i=
SK-MM-2 NGnUdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSwMVUxOCCwTR?= NG\sWog1QCCq Mni1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MUeyOVI6Pjl5OB?=
U-266 M1PnWGFxd3C2b4Ppd{BCe3OjeR?= MlvFNE02OCCwTR?= NX62UG1VOjRiaB?= MUjpcoR2[2W|IHHwc5B1d3Orcx?= NEOyNFYzPTJ7Nkm3PC=>
INA-6  MYTBdI9xfG:|aYOgRZN{[Xl? MoXzNE02OCCwTR?= M{LuTlI1KGh? MWXpcoR2[2W|IHHwc5B1d3Orcx?= NIH0[|QzPTJ7Nkm3PC=>
MCF7 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPTO|IhcA>? MlrITWM2OD1zMzFCtUA3KG6P NGnFUnMzPTJ{MEKyOS=>
MCF7-TamR6 MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37hTFczKGh? MVzJR|UxRThiwsGgOkBvVQ>? M{jMNVI2OjJyMkK1
MCF7-TamR7 NFGyOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XWN|czKGh? NI\LTFZKSzVyPUigxtEhOyCwTR?= NWTJVGVTOjV{MkCyNlU>
MCF7-TamR8 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm1O|IhcA>? M3nLd2lEPTB;MUWgxtEhPiCwTR?= MkfmNlUzOjB{MkW=
MCF7-TamC3 M1Ky[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zpO|czKGh? NFHwZlZKSzVyPU[gxtEhOyCwTR?= MlfONlUzOjB{MkW=
MCF7-TamC6 NFTwb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYC3NkBp NIDUV5RKSzVyPU[gxtEhOC5zIH7N NHTLZZgzPTJ{MEKyOS=>
MDA-MB-231 NX\JUYgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7WO|IhcA>? MWPJR|UxRTViwsGgNUBvVQ>? NF\sfoozPTJ{MEKyOS=>
SK-BR-3 M4fXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Dl[VczKGh? NYXrbmRvUUN3ME23JOKyKDBwMzDuUS=> MkLsNlUzOjB{MkW=
Eca109 MnrwSpVv[3Srb36gRZN{[Xl? MmLMNU02OCCwTR?= NHfTWWc1QCCq MXzEUXNQ NX7QZ2dje3WycILld5NmeyC|dYL2bZZqdiCneIDy[ZN{cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M4foZlI2OTN7M{m1
TE13 M1zRTWZ2dmO2aX;uJGF{e2G7 NWjyOlRYOS13MDDuUS=> MYe0PEBp M1;XS2ROW09? M32zcZN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHu0NoEzPTF|OUO5OS=>
Eca109 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jBeFAuOTByIH7N Ml:5NlQwPDhiaB?= NX\HSIVlTE2VTx?= Mm\a[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4mz[lI2OTN7M{m1
TE13 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHpNE0yODBibl2= MlTrNlQwPDhiaB?= NXnkNYpCTE2VTx?= NVTpUWFR\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NF7Cd5EzPTF|OUO5OS=>
MT-3 NH\qOGxMcW6jc3WgRZN{[Xl? NGjXV5k4OiCq M2qwUmROW09? M1XnWmlEPTB;Mj64OkDDuSByLkW0JI5OKG[xcjDEVlQh\XiycnXzd4lwdg>? MlnrNlQ5PjZ3OEW=
MDA-MB-468 NUfzPXdPU2mwYYPlJGF{e2G7 M4LpO|czKGh? M1G1dGROW09? M{jNbmlEPTB;MD6xNUDDuSByLkCxJI5OKG[xcjDEVlQh\XiycnXzd4lwdg>? MXOyOFg3PjV6NR?=
SUM-159 MkW5T4lv[XOnIFHzd4F6 M4TOVlczKGh? M2PmS2ROW09? MkDKTWM2OD1zLkeyJOKyKDBwM{Ogcm0h\m:{IFTSOEBmgHC{ZYPzbY9v NVvSOnF4OjR6Nk[1PFU>
MT-3 MXHLbY5ie2ViQYPzZZk> M2LNeFczKGh? MkPlSG1UVw>? MmPhTWM2OD13ND6xNUDDuSB2LkOyJI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? MXeyOFg3PjV6NR?=
MDA-MB-468 M1fzV2tqdmG|ZTDBd5NigQ>? MoXoO|IhcA>? MWPEUXNQ M3P0dGlEPTB;MD6wO{DDuSByLkCyJI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? NUHmPItkOjR6Nk[1PFU>
SUM-159 MVPLbY5ie2ViQYPzZZk> M3n4flczKGh? NVTlSIlFTE2VTx?= Mmm3TWM2OD14OT60JOKyKDRwMkOgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v MX:yOFg3PjV6NR?=
MT-3 + NAC Mmr1T4lv[XOnIFHzd4F6 MVO3NkBp NFvKNplFVVOR NIP3fmxKSzVyPUW2MlIhyrFiMj6wO{BvVSCob4KgSHI2KGW6cILld5Nqd25? NFnj[3YzPDh4NkW4OS=>
MT-3 + SB203580 MVrLbY5ie2ViQYPzZZk> Mki3O|IhcA>? NFvGTpRFVVOR NVO2N2FwUUN3ME2zPE41OSEEsTC1MlAzKG6PIH\vdkBFWjViZYjwdoV{e2mxbh?= NFrIUG0zPDh4NkW4OS=>
DB NYfTdWNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHkOpcyOCCwTR?= NInkZYEzPCCq NIG4dWxFVVOR MlX3bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u M{jkTFI1PDh4NUm1
SU-DHL-8 NXLjV|R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLSNVAhdk1? NFrGb4QzPCCq M{jze2ROW09? MVXpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= MXqyOFQ5PjV7NR?=
WSU-DLCL2 M4DGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrKdJcyOCCwTR?= MlvRNlQhcA>? MV7EUXNQ MX\pcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= M4\TPVI1PDh4NUm1
ACC-2 NV\ubpE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmwMVExOCCwTR?= Ml[4NlQhcA>? MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NUHhUWozOjR|N{C5PVU>
ACC-2 M2TZeWFxd3C2b4Ppd{BCe3OjeR?= NH\CdosxNTJyIH7N NF\sd2YzPCCq MlTNbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mnn0NlQ{PzB7OUW=
ACC-2 MVXGeY5kfGmxbjDBd5NigQ>? NWLtWlRGOC1{MDDuUS=> MV6yOEBp M{nSVYlv[3KnYYPld{B1cGViY3;ueoVze2mxbjDv[kBNSzOLIITvJGxEO0mL NVOwPGpUOjR|N{C5PVU>
BFTC905 M{DqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfzNE0yODByIH7N M4fpWFQ5KGkEoB?= M1flWmROW09? NUnXXnlEUUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mnn3NlQzQTd4NES=
T24 NXLLbpBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYW2blNZOC1zMECwJI5O M3rUUFQ5KGkEoB?= MknOSG1UVw>? M{jLbGlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NEW5ToczPDJ7N{[0OC=>
TSGH8301  NW\SN|Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XZbFAuOTByMDDuUS=> NHjzSGg1QCCqwrC= MULEUXNQ Mm\VTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3fWflI1Ojl5NkS0
BFTC909 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWewMVExODBibl2= MYG0PEBpyqB? MlLpSG1UVw>? MljHTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3:xZ|I1Ojl5NkS0
BFTC905 NVrXZVg{SXCxcITvd4l{KEG|c3H5 MX:yNEBvVQ>? Ml\LOFghcA>? M122bWROW09? MYfpcoR2[2W|IHHwc5B1d3Orcx?= MWqyOFI6PzZ2NB?=
BFTC905 M1WyVmZ2dmO2aX;uJGF{e2G7 MmHPNlAhdk1? Mm\qOFghcA>? NUnBOW1LTE2VTx?= M2nteYRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzOELVnJ MmHyNlQzQTd4NES=
A2780p NHu5WnhHfW6ldHnvckBCe3OjeR?= NVHwPGtDOC1zMECgcm0> MWSyOEBp NEPDbZZFVVOR MVfpcoR2[2W|IGP1dpZqfmmwIHTve45z\We3bHH0bY9vyqB? MUOyOFI3Ojh5NR?=
A2780cis MWnGeY5kfGmxbjDBd5NigQ>? NUHYZWs6OC1zMECgcm0> M2WzT|I1KGh? MnWzSG1UVw>? M3qxZYlv\HWlZYOgV5Vzfmm4aX6g[I94dnKnZ4XsZZRqd28EoB?= MnWxNlQzPjJ6N{W=
A2780p NVvibIdFSXCxcITvd4l{KEG|c3H5 M4D5[VUuOTByIH7N M2[0WFI1NzR6IHi= MUTEUXNQ NVHmdldZcW6lcnXhd4V{KGGyb4D0c5NqeyCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MV[yOFI3Ojh5NR?=
A2780cis M4nTPWFxd3C2b4Ppd{BCe3OjeR?= Mke2OU0yODBibl2= MYKyOE81QCCq NEfJZoNFVVOR NFXKNVBqdmO{ZXHz[ZMh[XCxcITvd4l{KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NHXac2YzPDJ4Mki3OS=>
SH-SY5Y M2\KNmFxd3C2b4Ppd{BCe3OjeR?= NYizfZFEOS9zMD:xNFAhyrWP M{fQbFczKGh? MnXpSG1UVw>? NUCze41xcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1LHdVI1OjV2NU[w
HL-60 M4G4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq5R2k4OsLiaB?= M3XTPWROW09? NUC3XZQzUUN3ME2wMlMhdk1? M1uwWVI{PjF6OE[y
U937  M1PTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInEe2Q4OsLiaB?= M1P2[GROW09? MmTzTWM2OD1yLkigcm0> M3\Ub|I{PjF6OE[y
HL-60  MVjGeY5kfGmxbjDBd5NigQ>? M4XvfVHDqM7:TR?= MnvROk8yOi9{NDDo MYDEUXNQ MX\pcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDzeZJ3cX[rbh?= NX3MZ3h4OjN4MUi4OlI>
U937  NH;pe|JHfW6ldHnvckBCe3OjeR?= NW[5[5htOcLizszN M4jsS|YwOTJxMkSgbC=> MmDNSG1UVw>? M1zqUolvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJN2en[rdnnu MWCyN|YyQDh4Mh?=
HL-60 MonaRZBweHSxc3nzJGF{e2G7 M1racFAvOS9zIN88US=> NF3pW5U5KGh? MojtSG1UVw>? MnHObY5lfWOnczDhdI9xfG:|aYO= NFHZW|MzOzZzOEi2Ni=>
Sk-NEP-1  NELydVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yyeVEuOTByMECgcm0> Mn75NlQhcA>? MWfEUXNQ NGjLeYJKSzVyPUGwNEBvVQ>? NFXTUWozOzJ4N{[5PS=>
SK-NEP-1  MlLlRZBweHSxc3nzJGF{e2G7 MmThOVAwOTByIH7N MWexNk8zPCCq MmS4SG1UVw>? NF3pdFFqdmS3Y3XzJIFxd3C2b4Ppdy=> NUHmZWFQOjN{Nke2PVk>
TC-32 NWPKUndRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPKV3BWOC5zLUGwNFAhdk1? NV3CZZZbTUN3ME2zMlAhdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M2LlN|IzQTZzN{[z
TC-71 NYHhNY43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorBNE4yNTFyMECgcm0> NHS5cJdGSzVyPUWuO{BvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NWDRbphDOjJ7NkG3OlM>
SK-ES-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW3NE4yNTFyMECgcm0> NX;EXlZ4TUN3ME2yMlghdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1z5c|IzQTZzN{[z
RD-ES NXLOOlRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfKNE4yNTFyMECgcm0> Mny0SWM2OD14LkKgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2DrR|IzQTZzN{[z
HEK293 NIPGbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MViwMlEuOTByMDDuUS=> NWfoUGZTTUN3ME2yN{4xKG6PLDDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHHmfYszOjl4MUe2Ny=>
M059J MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSwMVUxKG6P NV;kV4RSPDhiaB?= MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Ml7rNlI4PzBzMUC=
M059K MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKwMVUxKG6P MW[0PEBp MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4rre|IzPzdyMUGw
M059J NWHZT4VVSXCxcITvd4l{KEG|c3H5 MV[zNEBvVQ>? MmTRNlQhcA>? Ml7vbY5lfWOnczDhdI9xfG:|aYO= MonVNlI4PzBzMUC=
M059K Mnm4RZBweHSxc3nzJGF{e2G7 MU[zNEBvVQ>? NE\vdYkzPCCq NE\LU2hqdmS3Y3XzJIFxd3C2b4Ppdy=> MlvFNlI4PzBzMUC=
PANC-1 MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVywMlAyNTFyMECgcm0> NWHHS5NUPDhiaB?= NXTKboYzUUN3ME2zMlY6KG6P MlXJNlI4OjN6N{G=
MIAPaCa-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOwMlAyNTFyMECgcm0> MXy0PEBp MXPJR|UxRTJ7LkO2JI5O MY[yNlczOzh5MR?=
BxPC-3 NX;zRpd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTJZYJWOC5yMT2xNFAxKG6P NFXZUZc1QCCq MoDETWM2OD1|MD6yOkBvVQ>? NHLnXGIzOjd{M{i3NS=>
PANC-1 MXTGeY5kfGmxbjDBd5NigQ>? MXOwMVExODBibl2= MVGyOEBp M2\kWIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gXGlCWCCjbnSgd5Vzfmm4aX6g[ZhxemW|c3nvci=> NFvxfW4zOjd{M{i3NS=>
MIAPaCa-2 MYjGeY5kfGmxbjDBd5NigQ>? MoDDNE0yODByIH7N MVSyOEBp NYTBblMxcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v NF;jdY8zOjd{M{i3NS=>
BxPC-3 MXvGeY5kfGmxbjDBd5NigQ>? MoXxNE0yODByIH7N NWWxOJBHOjRiaB?= MkjwbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDYTWFRKGGwZDDzeZJ3cX[rbjDlfJBz\XO|aX;u NGfhb2EzOjd{M{i3NS=>
RPMI-7951 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXxS2k2OD1|LkKgcm0> MoW3NlE4Ozd3MEK=
SK-MEL-5 NF3h[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfXSoluT0l3ME20MlIhdk1? M3z3R|IyPzN5NUCy
A375 NYTZbJM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7HTVUxRTZwMzDuUS=> NIW0bJkzOTd|N{WwNi=>
SK-MEL-28 NETOcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37BTGdKPTB;Nz62JI5O M3izd|IyPzN5NUCy
SK-MEL-2 NWLPelY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\6S2k2OD1zMTDuUS=> NVXqbIxpOjF5M{e1NFI>
DB MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzrOFjDqGh? M2nDU2dKPTB;Mz61JI5O NF23TZczOTJ|N{WwPC=>
Pfeiffer MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC3OFjDqGh? MXXHTVUxRTNwOTDuUS=> NFq5Z3QzOTJ|N{WwPC=>
SU-DHL-5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vENlQ5yqCq MWTHTVUxRTBwMkOgcm0> NHe4b4IzOTJ|N{WwPC=>
SU-DHL-8 MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT6OFjDqGh? NWn5VYN[T0l3ME2xMlQhdk1? NVKwe2FZOjF{M{e1NFg>
WSU-DLCL-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC3OFjDqGh? NYrG[5h2T0l3ME2xMlQhdk1? MV2yNVI{PzVyOB?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP; 

PubMed: 26771139     


YM155 treatment decreased survivin expression without affecting XIAP and induced cleavage of caspases. Protein expression (caspase-3, -7, -9, -8, PARP) was detected by Western Blot analysis. 

β-catenin / c-Myc / Cyclin D1 / CD44 ; 

PubMed: 26771139     


YM155 inhibited expression of CSC molecules. SGC-7901 cells were treated with YM155 at indicated doses for 24 hours. The protein levels of genes were determined by Western Blot.

p-STAT3 / STAT3 ; 

PubMed: 22723871     


Levels of phosphorylated STAT3 and expression of survivin were analyzed by Western blotting after a 24-hours treatment with YM155 and 48 hours after transfection of 40 nM siRNA.

26771139 22723871
Immunofluorescence
EGFR; 

PubMed: 22723871     


YM155 (10 nM) induced the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars: 10 µm.

PARP-1 / PAR ; 

PubMed: 26090615     


A. Nuclear accumulation of active PARP-1 in KYSE410 cells after 12 h of YM155 treatment was evaluated using immunofluorescent analysis. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. C. Accumulation of the poly-ADP polymer in KYSE410 was evaluated using immunofluorescent analysis after YM155 treatment for 12 h. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. 

22723871 26090615
Growth inhibition assay
Cell viability; 

PubMed: 29636860     


Cells were grown in 96-well plates for 24 h and treated with the indicated concentrations of YM155 or docetaxel for 72 h, and cell survival was determined by MTT assay.

29636860
In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

- Collapse
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A
Smiles CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID